- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00811538
Swiss Intravenous and Intra-arterial Thrombolysis for Treatment of Acute Ischemic Stroke Registry (SWISS)
Swiss Intravenous and Intra-arterial Thrombolysis for Treatment of Acute Ischemic Stroke Registry (SWISS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Intravenous thrombolysis (IVT) and intra-arterial thrombolysis (IAT) have been shown to be effective treatments for acute stroke in controlled randomized trials and meta-analyses. However, prospective studies comparing IVT and IAT have not been performed, and it is not known which patients benefit more from IVT or IAT. Non-invasive neurovascular imaging techniques such as magnetic resonance angiography (MRA) or computed tomography angiography (CTA) have the potential to improve patient selection for the optimal mode of thrombolytic therapy and provide data of pre-treatment neurovascular findings of patients treated with IVT. IAT series have identified several prognostic factors for favourable or poor outcome predictors such as vessel recanalization, location of the vascular occlusion or NIHSS at admission. Additional studies have shown that recanalization rates in patients with central ves-sel occlusions such as middle cerebral artery (MCA) main stem or MCA main branch or basilar artery (BA) is higher when treated with IAT compared to IVT. Therefore, the investigators hypothesize that IAT might be more efficacious in these patients.
Objective: Prospective observational multicenter registry with the following aims: To compare the safety and efficacy of IAT and IVT in patients with acute ischemic stroke. To improve safety of IAT and IVT by monitoring the in-hospital management.
Methods: Consecutive patients with acute ischemic stroke who are treated with IVT or IAT within 6 hours of symptom onset in a Swiss stroke unit will be eligible for this registry. Patients are given either intravenous rt-PA or receive IAT such as intra-arterial urokinase, intra-arterial rt-PA or mechanical endovascular recanalization techniques. Patient involvement in the registry shall not influence any treatment decision. Patients will undergo a complete diagnostic work up including a clinical neurological examination using the National Institutes of Health Stroke Scale (NIHSS) score on admission, laboratory examination, brain and neurovascular imaging, echocardiography, 24-hours ECG to determine stroke etiology using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. The treating physician will initiate secondary prevention of stroke as soon as possible. All patients will be examined by CT and CTA or MRI and MRA on day 1 and in any case of clinical deterioration to exclude intracranial haemorrhage and to assess recanalization of the occluded vessel (using the thrombolysis in myocardial infarction (TIMI) grading system). Clinical outcome will be evaluated on day 1 and at 3 months using the National Institute of Health Stroke Scale (NIHSS) score, modified Rankin Scale score (mRS), Barthel Index (BI), and assessing adverse events and quality of life. The proportion of patients with favourable outcome (mRS 0 to 2) at 3 months after IVT and IAT will serve as the primary outcome measure. In addition, subgroup analyses will be performed stratified by NIHSS, location of vessel occlusion, time to hospital admission and time to treatment. Secondary outcome measures will include quality of life and the proportion of patients with an excellent outcome (mRS 0 or 1) at 3 months, BI 75 to 100 at 3 months, mortality at 3 months, rapid neurological improvement during the first 24 hours, complete or partial recanalization, and symptomatic intracranial haemorrhage.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bern, Switzerland, 3010
- Dep. of Neurology, Bern University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18 years
- Intracranial arterial occlusion confirmed by conventional angiography, MRA or CTA
- National Institute of health Stroke Scale (NIHSS) score ≥ 4 or isolated aphasia or hemianopia
- Time to treatment < 6 hours
Exclusion Criteria
- Intracranial haemorrhage on CT scn or MRI
- History of intracranial haemorrhage or subarachnoid haemorrhage
- Platelet count < 100'000
- International normalized ration (INR) > 1.5
- Partial thromboplastin time (PTT) > 1.5 times the normal value
- Known hereditary of acquired haemorrhagic diathesis
- Pre-existing neurological deficit (mRS>2)
- Previous stroke that might interfere with the neurological assessment (mRS >2)
- Active gastric ulcer
- Major trauma within the preceding 3 months
- Major surgery within the past 4 weeks
- Childbirth within the previous 4 weeks
- Pregnancy
- Uncontrolled hypertension (>185/10 on repeated measures despite antihypertensive medication)
- Severe systemic disease with poor prognosis (e.g. cancer, severe heart failure)
- Intracranial neoplasm
- Combined IVT and IAT
- Combined Intravenous and Ultrasound Thrombolysis
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1 1 (Liv*)
i.v. thrombolysis with rtPA
|
i.V. thrombolysis with rtPa
|
2 (L*)
intraarterial thrombolysis
|
Endovascular treatment with i.a.
Urokinase or i.a.
rtPA or mechanical recanalization techniques
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
overall frequency of favourable clinical outcome (modified Rankin Scale 0 to 2), and unfavourable clinical outcome or death (modified Rankin Scale 3 to 6)
Time Frame: Day 90
|
Day 90
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
subgroup analyses will be performed stratified by NIHSS score
Time Frame: Day 90
|
Day 90
|
Excellent functional clinical outcome (modified Rankin Scale 0 or 1) and quality of life (measured by EuroQol and Stroke specific Quality of Life Scale)
Time Frame: Day 90
|
Day 90
|
All causes of mortality
Time Frame: Day 90
|
Day 90
|
Proportion of patients with rapid neurological improvement (more than 4 points on the NIHSS) during the first 24 hours after thrombolysis.
Time Frame: Day 1
|
Day 1
|
Complete or partial recanalization of the occluded artery (TIMI grade 2 or 3) assessed by CTA or MRA.
Time Frame: Day 1
|
Day 1
|
Symptomatic intracranial haemorrhages up to 24 hours after thrombolysis defined as homogeneous areas of haemorrhage, with or without mass effect or intraventricular extension with neurological deterioration
Time Frame: Day 1
|
Day 1
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Marcel Arnold, MD Prof., Dep. of Neurology, Bern University Hospital, Switzerland
- Principal Investigator: Krassen Nedeltechev, MD Prof., Kantonsspital Aarau, Switzerland
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 233/07
- 1446
- KEK 233/07 (Other Identifier: Ethics Committee)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Stroke
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on Intravenous Thrombolysis
-
University of LeicesterCompleted
-
Centre Hospitalier Universitaire VaudoisThe University of Texas Health Science Center, Houston; Charite University,... and other collaboratorsCompletedArterial Occlusive Diseases | Ischemic Stroke | Vertebrobasilar Insufficiency | Vertebral Artery IschemiaSwitzerland
-
Zhengzhou YuanRecruiting
-
Xiangya Hospital of Central South UniversityRecruiting
-
The First Affiliated Hospital of University of...Not yet recruiting
-
Acticor BiotechActive, not recruitingAcute Ischemic StrokeUnited States, Germany
-
Second Affiliated Hospital, School of Medicine,...RecruitingStroke, Acute IschemicChina
-
Changhai HospitalAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Wu Jieping... and other collaboratorsCompletedIschemic Stroke | Thrombosis | Large Vessel Occlusion | Thrombectomy | AlteplaseChina
-
Mayo ClinicTerminatedStroke | Ischemic StrokeUnited States
-
Acticor BiotechCompleted